Organization & Developments: Transmedics

Parents

TransMedics Group, Inc. (NASDAQ: TMDX)*

Children

*Addressing the huge problem of low supply of available donor organs and low utilization rates (65% to 80% of donated organs are wasted).
*Clinical trial data for Organ Care System (OCS) has shown double to triple utilization rates for donor organs and improved outcomes (50% or more reduction in post-transplant complications).
*Focuses on heart transplantation
*Medical device company strategically positioned to address patients with end-stage organ failure.
*ORGAN CARE SYSTEM (OCS) HEART SYSTEM
*Organ Care System is designed to maintain organs in a functioning state outside the human body to optimize their health and to a
*Potential breakthrough in the field of organ transplantation
*The company's Portable Organ Preservation System (POPS™) enables the preservation, resuscitation and transport of solid organs i
*The FDA awarded premarket approval to TransMedics’ OCS Heart System for use with organs from donors after circulatory death
2020: TransMedics Group - Long-Term Potential
2021: TransMedics gets 'clear win' after FDA panel backs liver preservation device: analysts
2021: TransMedics: Organ Transplant Preservation Technology With Upcoming Catalysts
2022: TransMedics Remains A Buy Heading Into Q3 Earnings_seekingalpha.com
2023: TransMedics Group: A Company In Flux
2023: TransMedics: Bold Moves And Strong Execution_seekingalpha.com
2024_ There's Been No Shortage Of Growth Recently For TransMedics Group's (NASDAQ:TMDX) Returns On Capital
2024: An Intrinsic Calculation For TransMedics Group, Inc. (NASDAQ:TMDX) Suggests It's 49% Undervalued
2024: Down 52%, Is TransMedics Stock a Buy on the Dip?
2024: The Paradigm Shift That Caused IBD 50 Stock TransMedics To Double This Year
2024: TransMedics Group Stock: Too Far, Too Fast
2024: TransMedics Group: Huge Opportunity In Organ Transplants
2024: TransMedics Group: Providing Long-Term Detailed Forecast And Upgrading To Buy
2024: TransMedics Group: Saving Lives, Delivering Returns
2024: TransMedics Group: This Could Be One Of The Biggest Moats In A Decade
2024: TransMedics: A Look At What Is Behind The Loss Of Sales Momentum In H2 2024
2024: TransMedics: Heart And Lungs Will Drive The Next Leg Higher
2024: TransMedics: Mistakes Have Been Made, Here's My Updated Outlook
2024: TransMedics: Overreaction To Temporary Headwinds (Rating Upgrade)
2024: TransMedics: Strong Business, Fully Valued Stock_ seekingalpha.com
2024: TransMedics: Strong Execution And Management Conservatism Is A Recipe For Success
2024: TransMedics' Organ Care: Critical Innovation With Lofty Expectations
2024: TransMedics' SWOT analysis: organ transplant innovator's stock faces growth hurdles
2024: TransMedics' Technology Poised To Transform Underpenetrated $8B Organ Transplant Market, Analyst Expects 22% Upside
2025: Breaking Into Healthcare: Why TransMedics Is My Bold First Move
2025: Buying The Dip: How TransMedics Is Set To Soar In A Potential $23 Billion Market_seekingalpha.com
2025: Transmedics raises 2025 revenue guidance to $565M-$585M with 28%-32% growth driven by OCS adoption
2025: TransMedics Reports Fourth Quarter and Full Year 2024 Financial Results
2025: TransMedics ups revenue guidance on strength of its organ transport tech
2025: TransMedics: A Cash Burn Problem That's Hard To Ignore
2025: TransMedics: Aggressive Guidance Largely Ignored By The Market
2025: TransMedics: CEO Is Buying Shares Ahead Of A Potentially Concerning Q3
2025: TransMedics: Data Points To Strong Second Quarter, But Beware Of The Second Half
2025: TransMedics: Exceptional Q1 Undermines The Short Narrative
2025: TransMedics: Expectations Remain Sky-High Despite Recent Stock Drop
2025: TransMedics: Extremely Undervalued And Extremely Innovative
2025: TransMedics: Misplaced Fear
2025: TransMedics' Turnaround: The Organ Transplant Leader Is Still A Buy

Jumps

*Key People: TransMedics
Finance & Acquisitions: TransMedics

Made with TheBrain